NCT06743126 2026-04-13
SUPRAME
Immatics US, Inc.
Phase 3 Recruiting
Clinical Trials
5 trialsNCT01721746 2022-04-19
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Bristol-Myers Squibb
Phase 3 Completed
NCT01006252 2018-07-17
SUMMIT-1
Eli Lilly and Company
Phase 3 Terminated
NCT00110019 2015-10-19
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 3 Completed
NCT00522834 2014-03-04
Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma
Synta Pharmaceuticals Corp.
Phase 3 Terminated